Vitamin strategy may curb risk of second stroke
Posted on: Tuesday, 8 November 2005, 14:14 CST
NEW YORK (Reuters Health) - A high-dose vitamin supplement may help reduce the risk of a second stroke, as well as death and cardiac events, according to a study published in the journal Stroke this month. The supplement consisted of vitamins B9 (folate), B6, and B12, which are known to reduce blood levels of homocysteine -- an amino acid linked to heart disease.
In a previous report from the Vitamin Intervention for Stroke Prevention (VISP) study group, the combined vitamin therapy did not reduce recurrent stroke and cardiac events, but it turned out that the trial included patients who were not likely to benefit from the treatment.
"The VISP trial included patients with deficiency of vitamin B12 who were unlikely to respond to our treatment, as well as patients with renal failure, who would not respond as well to vitamin therapy," Dr. David J. Spence of the Stroke Prevention and Atherosclerosis Research Center in Ontario, Canada told Reuters Health.
When Spence and colleagues re-analyzed the results in a subgroup of 2,155 subjects deemed most likely to respond to treatment, the combined vitamin therapy did appear to have a beneficial effect on recurrence of stroke and cardiac events.
Specifically, the team compared results of low-dose vitamin versus high-dose vitamin therapy and found that high-dose vitamin supplements reduced recurrent stroke, death and heart disease by 21 percent. When they subdivided patients by baseline levels of vitamin B12, thus identifying those with difficulties absorbing the vitamin, the differences between the low-dose and high-dose groups became greater.
"It is too early to conclude that vitamin therapy to lower total homocysteine is ineffective in the prevention of cardiovascular events," said Spence.
He and colleagues suggest that in the modern age in which grains are fortified with folate, the response to vitamin therapy for lowering homocysteine largely depends on B12 levels of the patients. Higher doses of B12, in addition to other therapies, will be required to reduce homocysteine, and thus to reduce stroke and the combined end point of stroke, death, and heart attack.
SOURCE: Stroke, November 2005.
Source: REUTERS
Related Articles
- Controlling Perioperative Hypertension With Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses
- Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
- OPTIMIZERx Helps Patients Reduce Rising Prescription Drug Co-Pay Costs
- New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
- New Study Furthers Understanding of the Role of Dual Antiplatelet Therapy in the Prevention Of Atherothrombotic Events, Including Heart Attack, Stroke or Cardiovascular Death in Broad Population
- Critical Therapeutics Completes Dosing of First Patient in Clinical Trial of Intravenous Zileuton
- NYU Medical Center Rusk Institute of Rehabilitation Medicine Helps Stroke & TBI Patients Reduce Vision Loss With NovaVision VRT
- Patient Weaned Off Artificial Heart Pump
- Benefits Found in High Doses of Statins; Reducing Cholesterol in Heart Patients Lowers Risk of Heart Attacks, Strokes, 5-Year Study Shows
- Dexmedetomidine Infusion Without Loading Dose in Surgical Patients Requiring Mechanical Ventilation: Haemodynamic Effects and Efficacy
 |
 |
User Comments (0)
RSS Feeds